Zalicus Inc. (ZLCS) Publishes Data on Selective Estrogen Receptor Modulators for the Treatment of Infectious Disease
6/20/2013 9:45:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has published preclinical data in Science Translational Medicine showing the beneficial effects of applying the Zalicus combination high-throughput screening (cHTS) technology for the potential treatment of ebolavirus (EBOV) infections. In the paper entitled “FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection,” the scientists, including drug developers from Zalicus and collaborators from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and investigators from the University of Virginia School of Medicine (UVA), describe screening a series of approved drugs and select molecular probes to identify drugs with antifilovirus activity.
Help employers find you! Check out all the jobs and post your resume.
comments powered by